Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Literature DB >> 29263442

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

A Pardanani¹, J Gotlib², A W Roberts³, M Wadleigh⁴, S Sirhan⁵, J Kawashima⁶, J A Maltzman⁶, L Shao⁶, V Gupta⁷, A Tefferi¹.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 29263442 DOI： 10.1038/leu.2017.330

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

× No keyword cloud information.

15 in total

Review 1. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors: A Tefferi; J W Vardiman
Journal: Leukemia Date: 2007-09-20 Impact factor: 11.528

2. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Authors: Vikas Gupta; Ruben A Mesa; Michael W N Deininger; Candido E Rivera; Shireen Sirhan; Carrie Baker Brachmann; Helen Collins; Jun Kawashima; Yan Xin; Srdan Verstovsek
Journal: Haematologica Date: 2016-09-15 Impact factor: 9.941

3. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

Authors: R A Abdelrahman; K H Begna; A Al-Kali; W J Hogan; M R Litzow; A Tefferi
Journal: Leukemia Date: 2014-09-25 Impact factor: 11.528

4. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.

Authors: Jeffrey W Tyner; Thomas G Bumm; Jutta Deininger; Lisa Wood; Karl J Aichberger; Marc M Loriaux; Brian J Druker; Christopher J Burns; Emmanuelle Fantino; Michael W Deininger
Journal: Blood Date: 2010-04-12 Impact factor: 22.113

5. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors: Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743

6. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors: Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245

Review 7. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors: Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal: Blood Date: 2006-05-04 Impact factor: 22.113

8. A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors: Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal: N Engl J Med Date: 2005-04-28 Impact factor: 91.245

9. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

Authors: K A Monaghan; T Khong; C J Burns; A Spencer
Journal: Leukemia Date: 2011-07-26 Impact factor: 11.528

10. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors: A Pardanani; R R Laborde; T L Lasho; C Finke; K Begna; A Al-Kali; W J Hogan; M R Litzow; A Leontovich; M Kowalski; A Tefferi
Journal: Leukemia Date: 2013-03-05 Impact factor: 11.528

18 in total

1. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Review 2. Management of Myelofibrosis-Related Cytopenias.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2018-06 Impact factor: 3.952

Review 3. JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Blood Date: 2017-05-12 Impact factor: 22.113

Review 4. Myelofibrosis: an update on drug therapy in 2016.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Expert Opin Pharmacother Date: 2016-11-07 Impact factor: 3.889

5. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors: Prithviraj Bose
Journal: Expert Opin Orphan Drugs Date: 2019-09-24 Impact factor: 0.694

Review 6. The role of JAK inhibitors in hematopoietic cell transplantation.

Authors: Rachel B Salit
Journal: Bone Marrow Transplant Date: 2022-04-06 Impact factor: 5.174

Review 7. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors: A Yacoub; O Odenike; S Verstovsek
Journal: Curr Hematol Malig Rep Date: 2014-12 Impact factor: 3.952